AzTrials
AzTrials

Peritoneal CarcinomatosisPhase 1PIPAC-NAL-IRINCT05277766

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

A Phase 1 study testing PIPAC with Nal-IRI in people with Peritoneal Carcinomatosis and Peritoneal Metastases, run by University Hospital, Ghent at 1 site in Belgium.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
PIPAC with Nal-IRI
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteBelgium
Study dates
21 Nov 2022to 1 Aug 2027
Phase
Phase 1

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable peritoneal carcinomatosis
  • Estimated life expectancy > 6 months; > 3 months if primary cancer is pancreatic
  • Age ≥ 18 years
  • Adequate performance status (Karnofsky index > 60% and WHO performance status < 2)
  • Written informed consent obtained prior any act of the research

Who cannot join

  • Concomitant systemic (IV) treatment with irinotecan (either as monotherapy or as part of a combination regimen such as FOLFIRI, CAPIRI, or FOLFOXIRI)
  • Pregnancy or breastfeeding during the clinical study
  • Patients of childbearing age unable or unwilling to provide effective contraception during the study and until the end of relevant exposure (extended by 30 days (female participants) or 120 days (male participants) since the IMP is genotoxic).
  • Known allergy or intolerance to irinotecan
  • Significant amount of ascites detectable (exceeding 3l in volume)
  • Intestinal or urinary tract obstruction
Show all 15Show fewer
  • Extensive hepatic and/or extra-abdominal metastatic disease
  • Impaired renal function (serum creatinine > 1.5 mg/dl or calculated GFR (CKD-EPI) < 60 mL/min/1.73 m²
  • Impaired liver function (serum total bilirubin > 1.5 mg/dl, except for known Gilbert's disease)
  • Platelet count < 100.000/µl
  • Hemoglobin < 9g/dl
  • Neutrophil granulocytes < 1.500/ml
  • Patients known to use:
  • CYP3A4 inducers (rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, St John's wort)
  • inhibitors of CYP3A4 (clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (atazanavir, gemfibrozil, indinavir, regorafenib)

Trial locations and contacts

1 site in 1 country.

Belgium1 site

  • UZ Ghent

    Ghent, East-Flanders, 9000

Other trials in Belgium

About this study

Official title: Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.

Read the detailed description

Peritoneal metastases (PM) are a common manifestation of gastrointestinal cancer. The prognosis of patients with PM is particularly poor, and response to systemic chemotherapy is worse compared to parenchymal metastatic cancer in the liver or lungs. In addition, patients with PM frequently develop debilitating symptoms such as intractable ascites, bowel obstruction, or ureteric obstruction, resulting in a severely compromised quality of life.

In selected patients with widespread PM, pressurized intraperitoneal aerosol chemotherapy (PIPAC) holds considerable promise. Briefly, PIPAC combines laparoscopy with intraperitoneal (IP) administration of chemotherapy as an aerosol, which is generated by a nebulizer. The pharmacokinetic (PK) and clinical advantages of PIPAC may be further enhanced by using nanosized anticancer drugs. Nal-IRI (Onivyde) is a nanoliposomal formulation of irinotecan (Camptothecin-11 (CPT-11)), with a markedly superior efficacy when compared with free CPT-11 in human breast and colon cancer xenograft models.

This is a phase I clinical study with aerosolized IP Nal-IRI in patients with PM from GI cancer. In this phase I study, dose escalation will be combined with pharmacokinetic/pharmacodynamic modelling which incorporates, in addition to plasma, tumour tissue, and peritoneal drug concentrations, biomarkers of toxicity and efficacy.

Being tested
PIPAC with Nal-IRI
Keywords
PIPAC, Nal-IRI, Peritoneal carcinomatosis, dose-finding study, pharmacokinetics, pharmacodynamics, safety and efficacy, Onivyde, Primary gastrointestinal cancer, Colorectal cancer, Small bowel cancer, Appendix cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, dose-escalation study, Peritoneal metastases
Medical subject headings
Peritoneal Neoplasms, Colorectal Neoplasms, Appendiceal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Bile Duct Neoplasms, Cholangiocarcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PIPAC with Nal-IRIDrug

    Also called Onivyde

    Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.

Study groups in NCT05277766
Study groupRoleWhat they receive
Nal-IRI (Onivyde) - 30mg/m²ExperimentalPIPAC with Onivyde (30 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
Receives: Drug: PIPAC with Nal-IRI
Nal-IRI (Onivyde) - 45mg/m²ExperimentalPIPAC with Onivyde (45 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
Receives: Drug: PIPAC with Nal-IRI
Nal-IRI (Onivyde) - 60mg/m²ExperimentalPIPAC with Onivyde (60 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
Receives: Drug: PIPAC with Nal-IRI
Nal-IRI (Onivyde) - 75mg/m²ExperimentalPIPAC with Onivyde (75 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
Receives: Drug: PIPAC with Nal-IRI
Nal-IRI (Onivyde) - 90mg/m²ExperimentalPIPAC with Onivyde (90 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
Receives: Drug: PIPAC with Nal-IRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximally tolerated dose (MTD) of Nal-IRI

    Dose limiting toxicities will be monitored.

    Measured: Within 14 weeks of the start of the treatment

Secondary outcomes (16)

  1. Recommended phase 2 dose

    Define the dose recommended to use in a follow-up phase 2 trial based on incidence of DLT and toxicity data scored with CTCAE v5.0 for chemotherapy related toxicity.

    Measured: 6 months after last subject's third PIPAC

  2. Surgical morbidity will be measured

    This will be estimated with the Dindo-Clavien classification and the comprehensive complication index (CCI).

    Measured: 6 months after third PIPAC

  3. Maximum concentration (Cmax) of nanoliposomal irinotecan

    Determined for CPT-11, SN-38 and SN-38G in plasma and tumor tissue using UPLC-MS/MS.

    Measured: Plasma at 10 timepoints: T= pre-dose (0 minutes=start nebulization), T=30 minutes, T=1.5 hour, T=2.5 hours, T=6 hours, T=24 hours, T=72 hours, T=168 hours, T=336 hours, T=504 hours // Tissue: T= pre-dose (0 minutes=start nebulization), T = 30 minutes

  4. Time to reach maximum concentration (Tmax) of nanoliposomal irinotecan

    Determined for CPT-11, SN-38 and SN-38G in plasma and tumor tissue using UPLC-MS/MS.

    Measured: Plasma at 10 timepoints: T= pre-dose (0 minutes=start nebulization), T=30 minutes, T=1.5 hour, T=2.5 hours, T=6 hours, T=24 hours, T=72 hours, T=168 hours, T=336 hours, T=504 hours // Tissue: T= pre-dose (0 minutes=start nebulization), T = 30 minutes

  5. Area under the curve (AUC0h-24h) of nanoliposomal irinotecan

    Determined for CPT-11, SN-38 and SN-38G in plasma and tumor tissue using UPLC-MS/MS.

    Measured: Plasma at 10 timepoints: T= pre-dose (0 minutes=start nebulization), T=30 minutes, T=1.5 hour, T=2.5 hours, T=6 hours, T=24 hours, T=72 hours, T=168 hours, T=336 hours, T=504 hours // Tissue: T= pre-dose (0 minutes=start nebulization), T = 30 minutes

  6. Volume of distribution (Vd) of nanoliposomal irinotecan

    Determined for CPT-11, SN-38 and SN-38G in plasma and tumor tissue using UPLC-MS/MS.

    Measured: Plasma at 10 timepoints: T= pre-dose (0 minutes=start nebulization), T=30 minutes, T=1.5 hour, T=2.5 hours, T=6 hours, T=24 hours, T=72 hours, T=168 hours, T=336 hours, T=504 hours // Tissue: T= pre-dose (0 minutes=start nebulization), T = 30 minutes

  7. Clearance (Cl) of nanoliposomal irinotecan

    Determined for CPT-11, SN-38 and SN-38G in plasma and tumor tissue using UPLC-MS/MS.

    Measured: Plasma at 10 timepoints: T= pre-dose (0 minutes=start nebulization), T=30 minutes, T=1.5 hour, T=2.5 hours, T=6 hours, T=24 hours, T=72 hours, T=168 hours, T=336 hours, T=504 hours // Tissue: T= pre-dose (0 minutes=start nebulization), T = 30 minutes

  8. Elimination half-life (T1/2) of nanoliposomal irinotecan

    Determined for CPT-11, SN-38 and SN-38G in plasma and tumor tissue using UPLC-MS/MS.

    Measured: Plasma at 10 timepoints: T= pre-dose (0 minutes=start nebulization), T=30 minutes, T=1.5 hour, T=2.5 hours, T=6 hours, T=24 hours, T=72 hours, T=168 hours, T=336 hours, T=504 hours // Tissue: T= pre-dose (0 minutes=start nebulization), T = 30 minutes

  9. Pharmacodynamics (PD) of nanoliposomal irinotecan will be analysed with the Peritoneal regression grading score (PRGS)

    Evaluated on tumor biopsies to determine histological treatment response

    Measured: T= pre-dose (0 minutes= start nebulization)

  10. Pharmacodynamics (PD) of nanoliposomal irinotecan will be analysed by tumor biopsies.

    Tumour samples will be collected at the end of the aerosol delivery after each PIPAC procedure.

    Measured: T= 30 minutes

  11. Time-to-event endpoints

    To evaluate patient's follow-up, several time-to-event endpoints are recorded which include: overall survival (OS), progression free survival (PFS) and peritoneal progression free survival (PPFS).

    Measured: 12 months after last subjects last visit

  12. Quality of Life (The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, EORTC QLQ-C30)

    This will be investigated using the EORTC QLQ-C30 questionnaire. As to question 1 to 28: the scale varies from 1 (not at all) to 4 (very much). A higher value indicates a lower quality of life. The total score will be between 28 and 112.

    The scale of question 29 and 30 varies from 1 (very poor) to 7 (excellent). The higher the value, the better the quality of life. The total score will be between 2 and 14

    Measured: Pre-operatively (every PIPAC), week 2 (every PIPAC) and, at 3 months, 6months and 12 months after last PIPAC procedure

  13. Quality of Life (Functional Assessment of Cancer Therapy, FACT-G questionnaire)

    This will be investigated using the FACT-G questionnaire. The scale of all questions varies from 0 (not at all) to 4 (very much). The total score will be between 0 and 108. The lower the total score, the better the quality of life.

    Measured: Pre-operatively (every PIPAC), week 2 (every PIPAC) and, and at 3 months, 6months and 12 months after last PIPAC procedure

  14. Quality of Life (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) score)

    This will be investigated using the PRO-CTCAE™ questionnaire. The scale of all questions varies from 0 to 4 or 0 to 1 representing absent/present. PRO-CTCAE scores for each attribute (frequency, severity and/or interference) should be presented descriptively (eg. summary statistics or graphical presentations).

    Measured: Determined before each PIPAC, every 14th day after PIPAC and at 3 months, 6months and 12 months after last PIPAC procedure

  15. Pain assessment performed by patient (Visual Analog Scale (VAS), Pain )

    With this score, pain is assessed on a horizontal line, 100 mm in length, anchored by word descriptors at each end, no pain and very severe pain respectively. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks.

    Measured: Determined before each PIPAC procedure, one day postoperatively, and one week after the procedure.

  16. Overall treatment response

    Determined according to the RECIST criteria, if possible (measurable lesions on CT or MRI). When no target lesions available, overall treatment response (stable disease, partial response, or progressive disease) will be determined by incorporating PRGS, clinical signs and symptoms, tumor markers, imaging findings (other than target lesions, e.g. ascites volume).

    Measured: Determined 8 months after last subject last visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Mar 2022
  2. Study start21 Nov 2022
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion1 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Model description
Phase I study with dose escalation according to two-stage time-to-event continual reassessment method (TITE-CRM): 3x30 - 3x45 - 4x60 - 4x 75 - 16x90 mg/m2 (number of patients x assigned dose). Dose escalation is continued until dose-limiting toxicity (DLT) is observed. Only DLTs that take place within 14 weeks of the start of the treatment are considered. From that moment, TITE-CRM updates an initial prior estimate of the probabilities of DLT based on all available information, including patients with incomplete follow-up. Newly accrued patients are assigned the dose whose estimated probability of DLT at that time is closest to target probability. This method allows for continuous, staggered accrual of patients. The target-probability of DLT is 30%. The estimated MTD will be the dose whose estimated posterior probability of DLT is closest to that targeted probability.
Masking
None (open label)
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05277766
Sponsor's protocol ID
ONZ-2022-0120
Acronym
PIPAC-NAL-IRI
Status last verified
Jul 2026
First submitted
18 Feb 2022
Last updated
13 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in